# Bangarang Group

> Bangarang Group is a VC fund backing Medical, Health Care and Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 4
- Last investment: Jul 2022
- Lead investor: 50%
- Last updated: Aug 2026

Bangarang Group is a VC fund focused on Medical and Health Care. Bangarang Group

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 25% |
| Health Care | 1 | 25% |
| Biotechnology | 1 | 25% |
| Precision Medicine | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 25% |
| Funding Round | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SEngine Precision Medicine | SEngine Precision Medicine uses algorithms and 3D organoid technology to develop drugs with more efficacy. It empowers patients and oncologists with more informed treatment options. The company's technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The results decode themost effective and least toxic treatment options that DNA sequencing alone cannot reveal. Its proprietary platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs. | $10M | Series A | Jul 28, 2022 |  |
| SEngine Precision Medicine | SEngine Precision Medicine uses algorithms and 3D organoid technology to develop drugs with more efficacy. It empowers patients and oncologists with more informed treatment options. The company's technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The results decode themost effective and least toxic treatment options that DNA sequencing alone cannot reveal. Its proprietary platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs. | $10M | Series A | Jul 28, 2022 |  |
| SEngine Precision Medicine | SEngine Precision Medicine uses algorithms and 3D organoid technology to develop drugs with more efficacy. It empowers patients and oncologists with more informed treatment options. The company's technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The results decode themost effective and least toxic treatment options that DNA sequencing alone cannot reveal. Its proprietary platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs. | $5.1M | Series A | Oct 02, 2019 |  |
| SEngine Precision Medicine | SEngine Precision Medicine uses algorithms and 3D organoid technology to develop drugs with more efficacy. It empowers patients and oncologists with more informed treatment options. The company's technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The results decode themost effective and least toxic treatment options that DNA sequencing alone cannot reveal. Its proprietary platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs. | $3M |  | Oct 29, 2018 |  |

4 of 4 investments shown.

## Co-investors
- [Alethea Capital Management](https://shizune.co/investors/profile/alethea-capital-management) — VC Fund, 2 deals together
- Vincere Capital — VC Fund, 2 deals together
- [Washington Research Foundation](https://shizune.co/investors/profile/washington-research-foundation) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Bangarang Group invest in?

Bangarang Group invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Funding Round stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bangarang Group last invest?

The most recent investment recorded for Bangarang Group closed in Jul 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co